The Buy rating reiteration by HC Wainwright & Co. analyst Yi Chen indicates a positive outlook for Renalytix's stock. The maintained $5 price target suggests that the analyst believes the stock has potential for growth in the short term. This news is likely to have a positive impact on the stock price, as it reinforces investor confidence in the company's prospects.